المؤلفون: Katsigianni, I., Skouvaklidou, E., Vounotrypidis, G., Deligeorgakis, D., Zisopoulos, D., Sakellariou, G., Vounotrypidis, P.

المصدر: Scientific Abstracts

الإتاحة: https://doi.org/10.1136/annrheumdis-2023-eular.5855Test

المؤلفون: Georgiadis, A., Theodoridou, A., Vounotrypidis, P., Zisopoulos, D., Kallitsakis, I., Kandyli, A., Migkos, M., Bournazos, I., Sidiropoulos, P., Efstathiou, M., Athanassiou, P., Haratsis, I., Petrikkou, E., Vassilopoulos, D.

المصدر: Value in Health ; volume 22, page S433 ; ISSN 1098-3015

مصطلحات موضوعية: Public Health, Environmental and Occupational Health, Health Policy

الإتاحة: https://doi.org/10.1016/j.jval.2019.09.191Test
https://api.elsevier.com/content/article/PII:S1098301519325690?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1098301519325690?httpAccept=text/plainTest

المؤلفون: Vounotrypidis, P., Sakellariou, G. T., Zisopoulos, D., Berberidis, C.

مصطلحات موضوعية: CASE REPORTS

وصف الملف: text/html

العلاقة: http://rheumatology.oxfordjournals.org/cgi/content/short/45/4/491Test; http://dx.doi.org/10.1093/rheumatology/kel041Test

الإتاحة: https://doi.org/10.1093/rheumatology/kel041Test
http://rheumatology.oxfordjournals.org/cgi/content/short/45/4/491Test

المؤلفون: Flouri, I.D. Markatseli, T.E. Boki, K.A. Papadopoulos, I. Skopouli, F.N. Voulgari, P.V. Settas, L. Zisopoulos, D. Iliopoulos, A. Geborek, P. Drosos, A.A. Boumpas, D.T. Sidiropoulos, P.

الوصف: Objective. To evaluate the 10-year drug survival of the first tumor necrosis factor inhibitor (TNFi) administered to patients with spondyloarthritis (SpA) overall and comparatively between SpA subsets, and to identify predictors of drug retention. Methods. Patients with SpA in the Hellenic Registry of Biologic Therapies, a prospective multicenter observational cohort, starting their first TNFi between 2004-2014 were analyzed. Kaplan-Meier curves and Cox regression models were used. Results. Overall, 404 out of 1077 patients (37.5%) discontinued treatment (followup: 4288 patient-yrs). Ten-year drug survival was 49%. In the unadjusted analyses, higher TNFi survival was observed in patients with ankylosing spondylitis (AS) compared to undifferentiated SpA and psoriatic arthritis [PsA; significant beyond the first 2.5 (p = 0.003) years and 7 years (p < 0.001), respectively], and in patients treated for isolated axial versus peripheral arthritis (p = 0.001). In all multivariable analyses, male sex was a predictor for longer TNFi survival. Use of methotrexate (MTX) was a predictor in PsA and in patients with peripheral arthritis. Absence of peripheral arthritis and use of a monoclonal antibody (as opposed to non-antibody TNFi) independently predicted longer TNFi survival in axial disease because of lower rates of inefficacy. Achievement of major responses during the first year in either axial or peripheral arthritis was the strongest predictor of longer therapy retention (HR 0.33, 95% CI 0.26-0.41 for Ankylosing Spondylitis Disease Activity Score inactive disease, and HR 0.35, 95% CI 0.24-0.50 for 28-joint Disease Activity Score remission). Conclusion. The longterm retention of the first TNFi administered to patients with SpA is high, especially for males with axial disease. The strongest predictor of longterm TNFi survival is a major response within the first year of treatment. © 2018 The Journal of Rheumatology.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::fbb07ef894ab98f4802b78b3512f3daaTest
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3002746Test

المؤلفون: Katsigianni, I., Skouvaklidou, E., Vounotrypidis, G., Deligeorgakis, D., Zisopoulos, D., Sakellariou, G., Vounotrypidis, P.

المصدر: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p2073-2073, 1/3p

المؤلفون: Flouri, I. Markatseli, T.E. Voulgari, P.V. Boki, K.A. Papadopoulos, I. Settas, L. Zisopoulos, D. Skopouli, F.N. Iliopoulos, A. Bertsias, G.K. Geborek, P. Drosos, A.A. Boumpas, D.T. Sidiropoulos, P.

مصطلحات موضوعية: musculoskeletal diseases, skin and connective tissue diseases

الوصف: Objective: To compare effectiveness, drug survival, and safety between infliximab, adalimumab, and etanercept, in a nationwide cohort of rheumatoid arthritis (RA) patients. Methods: This study is a prospective cohort study of 1208 active RA patients. Effectiveness, drug survival, and serious adverse events during entire follow-up (median 2.9 years) were monitored. Results: EULAR and CDAI responses were comparable between the three agents (EULAR good/moderate responses at 12 months ranged 76-79%). At 12 months, 15-23% achieved remission. For adalimumab and etanercept, adjusted hazard rate (HR) for EULAR/ACR remission (reference: infliximab) was 2.7 and 2.1 (95% confidence interval was 1.7-4.1 and 1.3-3.4, respectively); males (HR 1.6; 1.1-2.4), use of glucocorticoids (HR 2.0; 1.3-3.0), and swollen joint count >7 (HR 0.36; 0.24-0.55) were independent predictors. Five-year drug survival was 31%, 43%, and 49% for infliximab, adalimumab, and etanercept, respectively (p = 0.010). Infliximab was associated with significantly more withdrawals due to adverse events. Disease activity, CRP, and use of glucocorticoids predicted efficacy-related drug survival; age, use of methotrexate, and prior DMARDs failures predicted safety-related survival. Risk for serious infections was lower with adalimumab (odds ratio [OR] 0.62; 0.38-1.00) or etanercept (OR 0.39; 0.21-0.72) than infliximab, independent of the effects of age (OR 1.65; 1.37-2.00 per 10 years), tender joint count >10 (OR 1.86; 1.21-2.86), and glucocorticoids >35. mg/week (OR 1.83; 1.12-2.99). Conclusions: Response rates were comparable among anti-TNF agents. Overall, 5-year drug survival was below 50%, with infliximab demonstrating increased safety-related discontinuations. Remission rates are low in clinical practice. Strategies to increase effectiveness and long-term survival of anti-TNF agents in RA are needed. © 2014 Elsevier Inc.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::052eb81b088822e311d8e13681e1c804Test
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3126961Test

المؤلفون: Vasilopoulos, Y., Bagiatis, V., Stamatopoulou, D., Zisopoulos, D., Alexiou, I., Sarafidou, T., Settas, L., Sakkas, L., Mamuris, Z.

المصدر: http://www.scopus.com/inward/record.url?eid=2-s2.0-80055077775&partnerID=40&md5=2d290c75fa7fbee4b2826967f2a527c9Test.

مصطلحات موضوعية: Anti-CCP, Anti-TNF, Association, Pharmacogenetics, Polymorphism, adalimumab, cyclic citrullinated peptide antibody, etanercept, infliximab, leflunomide, methotrexate, rheumatoid factor, tumor necrosis factor inhibitor, antirheumatic agent, autoantibody, biological marker, cyclic citrullinated peptide, cyclopeptide, TNFRSF1A protein, human, TNFRSF1B protein, tumor necrosis factor alpha, tumor necrosis factor receptor 1, tumor necrosis factor receptor 2, adult, aged, allele, article, cohort analysis, controlled study

الوصف: Objective: To investigate the possible influence of tumour necrosis factoralpha (TNF), TNF receptor I (TNFRI) and TNF receptor II (TNFRII) gene polymorphisms on anti-TNF treatment responsiveness, stratified by autoantibody status. Methods: A Greek multi-centre collaboration was established to recruit a cohort of patients (n=100) with active RA treated with anti-TNF drugs. TNF g.-238G>A (rs361525), g.-308G>A (rs1800629), g.-857C>T (rs1799724), TNFRI c.36A>G (rs4149584) and TNFRII c.676T>G (rs1061622) polymorphisms were genotyped by PCRRFLP assays. Serum RF and anti-CCP antibody status were determined using commercially available kits. Single-SNP, haplotype and stratification by autoantibody status analyses were performed in predicting response to treatment by 6 months, defined as the absolute change in DAS28. Results: 31 patients (31%) were defined as non-responders due to failure to fulfill the DAS28 criteria. 79% and 66% were RF and anti-CCP positive, respectively. None of the genotyped SNPs was alone associated with responsiveness to drug treatment. However, after stratification by autoantibody status, carriage of TNFRII c.676G allele was associated with poorer response to drug treatment in anti-CCP positive patients (p=0.03), after 6 months of anti-TNF therapy. Conclusion: In concordance with previous studies, genetic polymorphisms alone cannot be used to safely predict clinical response to anti-TNF therapy however the combination of genetic factors and autoantibody status warrants further investigation in larger independent cohorts. © Clinical and Experimental Rheumatology 2011.

العلاقة: http://hdl.handle.net/11615/34381Test

الإتاحة: http://hdl.handle.net/11615/34381Test

المؤلفون: Vasilopoulos, Y., Bagiatis, V., Stamatopoulou, D., Zisopoulos, D., Alexiou, I., Sarafidou, T., Settas, L., Sakkas, L., Mamuris, Z.

المصدر: Clinical and Experimental Rheumatology ; ://WOS:000295351900015

مصطلحات موضوعية: pharmacogenetics, anti-TNF, association, anti-CCP, polymorphism, TUMOR-NECROSIS-FACTOR, GENE POLYMORPHISM, FUTURE-DIRECTIONS, THERAPY, DISEASE, POSITION-308, VALIDATION, INFLIXIMAB, ANTIBODIES, Rheumatology

الوصف: Objective. To investigate the possible influence of tumour necrosis factor-alpha (TNF), TNF receptor I (TNFRI) and TNF receptor II (TNFRII) gene polymorphisms on anti-TNF treatment responsiveness, stratified by autoantibody status. Methods. A Greek multi-centre collaboration was established to recruit a cohort of patients (n=100) with active RA treated with anti-TNF drugs. TNF g.-238G>A (rs361525), g.-308G>A (rs1800629), g.-857C>T (rsl 799724), TNFRI c.36A>G (rs4149584) and TNFRII c.676T>G (rs1061622) polymorphisms were genotyped by PCR-RFLP assays. Serum RF and anti-CCP antibody status were determined using commercially available kits. Single-SNP, haplotype and stratification autoantibody status analyses were performed in predicting response to treatment by 6 months, defined as the absolute change in DAS28. Results. 31 patients (31%) were defined as non-responders due to failure to fulfill the DAS28 criteria. 79% and 66% were RF and anti-CCP positive, respectively. None of the genotyped SNPs was alone associated with responsiveness to drug treatment. However, after stratification by autoantibody status, carriage of TNFRII c.676G allele was associated with poorer response to drug treatment in anti-CCP positive patients (p=0.03), after 6 months of anti-TNF therapy. Conclusion. In concordance with previous studies, genetic polymorphisms alone cannot be used to safely predict clinical response to anti-TNF therapy however the combination of genetic factors and autoantibody status warrants further investigation in larger independent cohorts.

العلاقة: http://hdl.handle.net/11615/34380Test

الإتاحة: http://hdl.handle.net/11615/34380Test

المؤلفون: Michalas, A, Louta, M, Loumos, V, Zisopoulos, D, Charitoudi, G

مصطلحات موضوعية: Absolute and proportional relative differentiation, Mobile agents, Quality of service, Cellular radio systems, Computer architecture, Differentiation (calculus), Internet, Internet protocols, Management, Network architecture, Public works, Telecommunication networks, Telecommunication services, Traffic surveys, Video signal processing, (SPM) classes, Admission Control scheme, Applied (CO), Diff-Serv, DiffServ architectures, DiffServ model, IP DiffServ, IP packets, Local computer, Management systems, Mobile agent technology, QoS (Quality of Service) guarantee, Qos differentiation, Quality of service (QoS) parameters, Real networks

العلاقة: 557; 558

الإتاحة: https://doi.org/10.1109/LCN.2006.322167Test

المؤلفون: Michalas, A., Louta, M., Loumos, V., Zisopoulos, D., Charitoudi, G.

المصدر: Proceedings 2006 31st IEEE Conference on Local Computer Networks; 2006, p557-558, 2p